Paul Tudor Jones’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Paul Tudor Jones’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-162,236	Closed	-$362K	–	1374
2017 Q4	$362K	Buy	162,236 +98,468	+154%	+$245K	0.01%	739
2017 Q3	$185K	Buy	+63,768	New	+$218K	﹤0.01%	970
2017 Q1	–	Sell	-18,376	Closed	-$112K	–	1633
2016 Q4	$112K	Buy	18,376 +232	+1%	+$1.21K	﹤0.01%	1293
2016 Q3	$100K	Sell	18,144 -16,241	-47%	-$76K	﹤0.01%	1337
2016 Q2	$131K	Sell	34,385 -13,776	-29%	-$46.7K	﹤0.01%	1492
2016 Q1	$133K	Buy	48,161 +26,087	+118%	+$94.5K	﹤0.01%	1582
2015 Q4	$125K	Sell	22,074 -20,432	-48%	-$125K	﹤0.01%	1507
2015 Q3	$225K	Sell	42,506 -12,909	-23%	-$99.9K	0.01%	1267
2015 Q2	$460K	Buy	55,415 +43,898	+381%	+$213K	0.01%	823
2015 Q1	$53K	Buy	+11,517	New	+$37.5K	﹤0.01%	1402

Other funds holding SGYP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Paul Tudor Jones's SGYP Position: Q1 2018 in Review

Paul Tudor Jones sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2018, closing a stake of 162,236 shares — an estimated $362K sold.

Paul Tudor Jones first reported a position in SGYP in Q1 2015 and held it in 10 quarters. The position peaked at $460K in Q2 2015. 147 funds tracked by Wall St. Rank hold SGYP as of Q1 2018.

Paul Tudor Jones reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2018 after selling out during the quarter.
Paul Tudor Jones sold 162,236 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2018, an estimated $362K.
Paul Tudor Jones first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2015 and held it in 10 quarters.
Paul Tudor Jones's Synergy Pharmaceuticals, Inc Common Stock position peaked at $460K in Q2 2015.
147 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2018.

Based on Tudor Investment Corp's 13F filing for Q1 2018, filed 15 May 2018.